Morgan Stanley raises target for West Pharmaceutical stock to USD 400.00
Morgan Stanley has upgraded West Pharmaceutical Services (WST) to Overweight and increased its price target from USD 365.00 to USD 400.00. This upgrade is driven by the company's strong performance, including a 13.8% increase in second-quarter revenue to USD 872.30 million and raised full-year organic revenue growth guidance. West Pharmaceutical, which manufactures vials and elastomer closures for injection systems, is benefiting from its exposure to injectable drug packaging, biologics, and GLP-1 treatments.
West Pharmaceutical Services stock reports strong Q2 growth ahead of results ?????????? no
West Pharmaceutical Services (WST) reported strong Q2 2026 results with revenue up 13.8% year-over-year to $872.3 million, beating analyst estimates. EPS of $2.37 also exceeded expectations. The company, which manufactures packaging and delivery devices for injectable medicines, will report its Q3 results on October 22, 2026, with analysts maintaining a "Moderate Buy" rating and an average price target of $382.
A director receives 44 units payable in shares at West Pharmaceutical (WST), bringing her balance to 350.87.
West Pharmaceutical Services Inc. director Janet Brutschea Haugen received an award of 44 phantom stock units on September 30, 2026. This award increased her post-award balance to 350.87 phantom stock units, which will be settled in shares upon her termination as a director. Additionally, she holds 2,114 shares of common stock directly, which includes 791 restricted stock units and dividend equivalents set to vest on the next annual shareholder meeting date.
Chemed Corp (CHE) Stock forecasts
Argus has raised its target price for Chemed Corp (CHE) to $544.00, an increase from its current price of $507.50. Chemed Corp is described as a company that purchases, operates, and divests subsidiaries to maximize shareholder value. The report provides a quantitative analysis for investors interested in the healthcare sector.
Josh Brown's 'Best Stocks in the Market:' West Pharmaceutical Services
Josh Brown, CEO of Ritholtz Wealth Management, discussed West Pharmaceutical Services on CNBC's "Halftime Report," highlighting it as one of the best stocks in the market. The segment focused on why this company stands out as a strong investment choice.
There’s one pharma-linked stock most investors have never heard of. It’s on Josh Brown’s list
Josh Brown and Sean Russo highlight West Pharmaceutical Services (WST) as a key player in the pharmaceutical industry that most investors overlook. West Pharmaceutical manufactures essential components for injectable drugs, benefiting from the growth of biologics, vaccines, insulin, and GLP-1 weight loss drugs. Despite a past downturn, the company's fundamentals are recovering strongly, driven by increased demand for high-value components and effective management changes, positioning it for potential further gains.
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
The article reviews the Q2 performance of several drug development inputs & services stocks, highlighting West Pharmaceutical Services (WST) as a strong performer. It details the revenue and EPS beats for companies like Azenta (AZTA), IQVIA (IQV), Charles River Laboratories (CRL), and Repligen (RGEN), noting their individual strengths and market reactions to their earnings reports. The industry as a whole saw strong Q2 results, with revenues beating estimates and share prices performing well post-earnings.
West Pharmaceutical Services stock reports 13.80 percent revenue growth
West Pharmaceutical Services (WST) reported a 13.80% year-over-year revenue growth in Q2 2026, reaching $872.30 million, and an EPS of $2.37, beating analyst expectations. The company also provided a fiscal 2026 EPS guidance of $8.85 to $9.05. Analysts maintain a "Moderate Buy" rating with an average target price above the current stock price, indicating potential for growth despite the stock being below its yearly high.
West Pharmaceutical Services stock attracts analyst coverage
West Pharmaceutical Services (WST) is attracting analyst attention with an average 12-month price target of USD 407.56 from 16 analysts as of September 30, 2026. The company reported strong Q2 2026 results, with revenue of USD 872.3 million and EPS of USD 2.37, both exceeding expectations. WST stock is trading near its 52-week high, with a market capitalization of USD 26.5 billion.
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
Smith+Nephew has launched its new EVOS PELVIC Plating System, expanding its trauma platform to include pelvic and acetabular fracture management. This move aims to strengthen the company's orthopedic trauma portfolio, broaden its addressable market, and enhance its competitive position in the orthopedic market. The system is designed to simplify complex procedures and is currently available in the United States.
ETFs Investing in Wingstop, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Wingstop, Inc. (WST). The ETFs are sorted by their market value and include details such as weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. This information helps investors identify diversified opportunities with potentially lower risk.
West Pharmaceutical stock ahead of the Xetra open as latest update dates to August 26
West Pharmaceutical stock is moving towards the Xetra open with no euro price or percentage change reported. The latest company update, dated August 26, 2026, concerns West's participation in upcoming investor conferences, as well as its Q2 2026 results and dividend announcement from July. West Pharmaceutical Services, Inc. (WST) specializes in designing and manufacturing containment and delivery systems for injectable drugs and healthcare products, operating through two segments: proprietary products and West Vantage.
West Pharmaceutical stock enters earnings watch with USD 382.00 target
West Pharmaceutical stock carries a "Moderate Buy" consensus from analysts, with an average 12-month price target of USD 382.00. The company's Q2 2026 revenue increased by 13.8% year-over-year to USD 872.3 million, and its next earnings report for Q3 2026 is scheduled for October 22, 2026. The stock is trading near its 52-week high, and investors will be looking for continued revenue growth in the upcoming report.
West Pharmaceutical Services stock last traded at USD 374.83 on September 28, 2026
West Pharmaceutical Services (WST) stock closed at USD 374.83 on September 28, 2026, marking a 1.17 percent increase. The company's management recently discussed growth drivers like demand in biologics and GLP-1 programs, along with near-term challenges such as a cyberattack and changes in the West Vantage business, at the Wells Fargo 21st Annual Healthcare Conference.
West Pharmaceutical Services, Inc. (WST) Latest Stock News & Headlines - Yahoo Finance
This article provides a compilation of recent news headlines and performance data for West Pharmaceutical Services, Inc. (WST) from Yahoo Finance. It highlights various analyst recommendations and updates from different financial news sources regarding WST and related healthcare companies. The article also includes stock performance metrics for WST compared to the S&P 500.
West Pharmaceutical Services, Inc. (WPS.F) Latest Stock News & Headlines - Yahoo Finance
This Yahoo Finance page provides the latest news and stock information for West Pharmaceutical Services, Inc. (WPS.F), including current stock price, recent news articles, and performance overview. The news highlights analyst recommendations, company developments, and market insights related to West Pharmaceutical and its peers. The stock has shown strong year-to-date and 1-year returns, outperforming the S&P 500.
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
Becton, Dickinson and Company (BDX) is positioned for growth due to its strategic transformation into a pure-play MedTech company, emphasizing innovation, and strategic partnerships. Despite strong fiscal results and a positive outlook, the company faces challenges from macroeconomic headwinds, reimbursement uncertainties, and intense competition. Investors are advised to retain the stock, with a Zacks Rank #3 (Hold), as it focuses on sustainable growth and margin expansion.
West Pharmaceutical Services (WST) Is Back In The Spotlight, What Is Catching Attention?
West Pharmaceutical Services (WST) has recently gained attention due to significant share price movements, including a 9.77% gain over the last month and a 34.02% year-to-date increase. Despite its strong performance, the stock trades at 46.1x earnings, which is above its fair ratio of 23.6x and the industry average. The article discusses whether its current strength is fully reflected in the price, with one narrative suggesting it's 8.6% undervalued based on future earnings and margin expansion, particularly from its contract manufacturing business.
West Pharmaceutical Services, Inc. (WST) Stock Price, News, Quote & History
This article provides a detailed financial overview of West Pharmaceutical Services, Inc. (WST), including its stock price, key financial metrics, performance against benchmarks, and analyst ratings. It outlines the company's business segments in proprietary and contract-manufactured products for injectable drugs and healthcare. The report also highlights recent earnings trends and valuation measures.
Top West Pharmaceutical Services (WST) Competitors 2026
This article analyzes West Pharmaceutical Services (WST) and compares it against five key competitors in the healthcare sector: Chemed (CHE), Encompass Health (EHC), Medline (MDLN), Alcon (ALC), and Solventum (SOLV). The comparisons cover various financial metrics, profitability, analyst recommendations, institutional ownership, media sentiment, and stock volatility. The analysis concludes with a summary for each comparison, indicating which company outperforms WST on a majority of the factors.
West Pharmaceutical Services stock gains after target rises
West Pharmaceutical Services (WST) stock saw gains after Morgan Stanley upgraded its rating to Overweight and raised its price target from USD 365 to USD 400. The company's Q2 2026 revenue of USD 872.3 million exceeded analyst estimates, and its earnings per share also beat expectations. The stock is currently trading near its 52-week high, reflecting strong financial performance and positive analyst sentiment.
West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says
Morgan Stanley projects that West Pharmaceutical Services (WST) is likely to exceed current Wall Street EPS estimates for 2027 due to an underestimation of its potential growth drivers. The firm highlights continued strength in Biologics and GLP-1 drugs as key factors that could lead to improved performance, forecasting a significant increase in adjusted EPS. This positive outlook suggests a potential re-rating for the stock as these growth drivers become more apparent to the broader market.
West Pharmaceutical stock rises 2.71 percent after analyst upgrade
West Pharmaceutical stock gained 2.71% after Morgan Stanley upgraded its rating from Equal-Weight to Overweight and raised its price target from $365 to $400. The upgrade was driven by Morgan Stanley's belief that the company's Q2 revenue beat expectations, with EPS exceeding consensus estimates. Despite strong performance, the stock's high P/E ratio of 47.58 suggests limited room for future setbacks.
West Pharmaceutical Services stock holds near its yearly range
West Pharmaceutical Services (WST) closed at $241.19 on September 21, 2026, positioning it near the lower end of its 52-week trading range. The stock's market capitalization stands at $17.6 billion. This valuation context follows a slight decline in both revenue and adjusted earnings per share in fiscal year 2025 compared to 2024.
WST: GLP 1 Is Only Part Of The Story, Margins Look More Durable
West Pharmaceutical Services (WST) has seen its financial outlook reaffirmed, with analysts updating their target price amid a stronger focus on GLP-1 exposure, high-value components, and improved contract manufacturing. The company's GLP-1 revenue is now estimated at 10% with high-teens growth, while high-value components and biologics exposure are expected to drive sustained margin benefits. Contract manufacturing, particularly the Dublin program, is also set to contribute significantly to earnings and margins.
Morgan Stanley Upgrades West Pharmaceutical Services to Overweight From Equalweight, Adjusts PT to $400 From $365
Morgan Stanley has upgraded West Pharmaceutical Services (WST) from Equalweight to Overweight, simultaneously raising its price target from $365 to $400. The article notes that West Pharmaceutical Services currently holds an average rating of "buy" among analysts, with a mean price target of $409.73. Access to the full MT Newswires article requires a premium subscription.
West Pharmaceutical Services (WST) Could Be 10% Undervalued On GLP 1 And Annex 1 Demand
West Pharmaceutical Services (WST) is potentially 10% undervalued, with a fair value estimated at $404, driven by increasing demand for GLP-1s and Annex 1 regulatory upgrades that favor its high-value injectable products. Despite a recent cyber incident and tariff-related cost inflation, the company's strategic focus on higher-margin products and biologics positions it for future growth. However, execution risks related to contract exits and tariffs could impact margins, and its current P/E ratio is higher than industry averages.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical Services (WST) is poised for growth due to strong demand for High-Value Products (HVPs), increasing biologics exposure, and regulatory-driven Annex 1 conversions. Despite concerns about tariff impacts and weak West Vantage results from a cyber incident, the company's shares have significantly outperformed the industry and S&P 500 year-to-date. Key growth drivers include its biologics franchise, Annex 1 upgrades providing multi-year revenue opportunities, and strong underlying momentum in delivery devices.
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
Avantor, Inc. has expanded its RIM single-use bioprocessing portfolio across the Asia Pacific (APAC) region, aiming to provide local biopharma manufacturers with improved access to its products. This strategic move, part of Avantor's "Revival" strategy, strengthens its position in the rapidly growing bioprocessing market by localizing manufacturing in China and leveraging regional supply chains. The expansion is expected to enhance supply reliability, shorten lead times, and support Avantor's long-term growth in the region.
Two global health firms plan layoffs in metro Phoenix
Two global health firms, West Pharmaceutical Services Inc. and Becton, Dickinson and Co., are planning layoffs in the Phoenix metropolitan area. West Pharmaceutical Services will lay off 98 employees in Scottsdale due to ceasing operations on a product line, while Becton, Dickinson and Co. is moving its manufacturing operations to other facilities.
West Pharmaceutical Services Inc. stock underperforms Friday when compared to competitors
West Pharmaceutical Services Inc. (WST) stock declined 1.17% on Friday, underperforming the broader market. This drop occurred during a mixed trading session where the S&P 500 Index rose, but the Dow Jones Industrial Average fell. The company's shares closed 6.14% below its 52-week high.
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
Avantor has expanded the availability of its RIM single-use bioprocessing portfolio across the Asia Pacific (APAC) region, aiming to strengthen its presence in a key biopharma manufacturing market and provide local customers with tailored solutions. This expansion, part of the company's broader Revival strategy, is expected to support long-term growth in its higher-value bioprocessing business. By manufacturing locally in China, Avantor seeks to improve supply reliability, shorten lead times, and better serve biopharma customers with customized solutions.
Market Movers RX: West Pharmaceutical Services Leads Gainers
This article announces that West Pharmaceutical Services is leading the gainers in the "Market Movers RX" segment. It appears to be a headline from a financial news source focused on the pharmaceutical industry. The provided content is primarily navigation and related article suggestions, rather than an in-depth report on West Pharmaceutical Services' performance.
West Pharma to cut 98 jobs as SmartDose production winds down in Arizona
West Pharmaceutical Services is set to cut 98 jobs at its Scottsdale, Arizona, operations. This decision follows the phasing out of SmartDose 3.5mL production, a consequence of the drug delivery system's sale to AbbVie. The job cuts are a direct result of this winding down of production.
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
Solventum Corporation (SOLV) is positioned for growth due to strong demand across its business segments, innovation investments, and a solid second-quarter 2026 performance with earnings surpassing estimates. The company's "Transform for the Future" program aims for significant cost savings, and its strategic growth drivers, including new product launches and segment-specific expansion, are expected to fuel future growth. However, potential raw material cost increases from a 3M supply agreement remain a concern.
Illumina Jumps 5.2% Amid Sector-Wide Rally
Illumina's stock surged 5.2% to $219.11 on Tuesday, participating in a broad sector-wide rally among diagnostics and research companies. This move, which saw other major players like TMO, WST, and MEDP also gain, indicates a positive shift in sentiment towards the broader industry. Despite recent headwinds, Illumina's strong performance suggests continued investor interest, though the rally's sustainability will depend on continued sector momentum.
West Pharmaceutical cuts 98 Scottsdale jobs after product sale
West Pharmaceutical Services is set to lay off 98 employees in Scottsdale, Arizona. This decision follows the company's plan to discontinue production for one of its product lines. The Philadelphia-headquartered manufacturer, which specializes in injectable medicines, filed a Worker Adjustment and Retraining Notification (WARN) in early September.
West Pharmaceutical (NYSE: WST) HR leader exercises options, then sells 7,524 shares
Annette F. Favorite, Sr. VP & Chief HR Officer at West Pharmaceutical Services Inc. (WST), exercised employee stock options for 7,524 shares and subsequently sold all 7,524 common shares in mid-September 2026 under a Rule 10b5-1 trading plan. The options were exercised at $89.64 per share, and the shares were sold in three transactions at prices ranging from $345 to $365 per share, resulting in an approximate pre-tax spread of $2.00 million. This transaction reduced her direct common stock holdings to 21,817.8098 shares.
West Pharmaceutical Services Insider Annette Favorite Executes Stock Options and Sells Shares in September 2026
Annette F. Favorite, Senior Vice President and Chief Human Resources Officer at West Pharmaceutical Services, exercised and sold 7,524 stock options across three separate transactions in September 2026 under a Rule 10b5-1 trading plan. She acquired shares at $89.64 per share and sold them at prices ranging from $345 to $365. After these transactions, Favorite directly owned 21,817.8098 common shares, and the specific stock option grant was fully depleted.
West Pharmaceutical Services at Morgan Stanley conference: growth broadens
West Pharmaceutical Services reported strong Q2 growth despite a cyber incident, raising full-year organic growth guidance to 10-11%. The company highlighted broad demand across drug containment and delivery, driven by high-value products like GLP-1 drugs, and identified multiple avenues for margin expansion and long-term growth. They also discussed strategic investments in HVP capacity, the multi-year opportunity from European Annex 1 rules, and potential M&A in elastomer-related solutions.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom (DXCM) is well-positioned for growth due to the significant potential of the continuous glucose monitoring (CGM) market, strong first-quarter 2026 performance, and a robust international presence. Despite competition, the company's shares have outperformed the industry and the S&P 500. Key growth drivers include strong global demand, potential expansion into the non-insulin Type 2 market with the CONNECT trial, and product differentiation from the G7 15 Day system.
West Pharmaceutical Services at Morgan Stanley conference: growth broadens
West Pharmaceutical Services reported strong second-quarter organic growth of 13%, exceeding expectations, and raised its full-year guidance to 10-11%. Despite a cyber incident, demand remains broad-based, driven by high-value products like GLP-1 drugs and regulatory upgrades in Europe and the U.S. The company sees significant long-term growth opportunities, margin expansion, and is evaluating inorganic growth strategies.
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Bausch + Lomb (BLCO) has received European CE Mark approval for its next-generation SeeLyra femtosecond laser, expanding its surgical portfolio in Europe. This platform offers precision for cataract, LASIK, and corneal therapeutic surgeries, featuring real-time visualization and a compact design for modern operating rooms. Despite a recent stock dip, the approval is expected to strengthen BLCO's market presence and support long-term growth, with further global regulatory approvals pending.
Is Now An Opportune Moment To Examine West Pharmaceutical Services, Inc. (NYSE:WST)?
This article examines West Pharmaceutical Services, Inc. (NYSE:WST) to determine if it is an opportune investment. It likely discusses factors such as its market position, financial performance, and future outlook to assess its current valuation and potential for growth. The analysis aims to help investors decide whether to consider the stock at its current price.
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
Revvity, Inc. announced its definitive agreement to acquire Human Cell Design (HCD), a biotechnology company specializing in human cell models for metabolic diseases. This acquisition aims to enhance Revvity's drug discovery and preclinical research capabilities, particularly for GLP-1-targeting treatments, by integrating HCD's human pancreatic beta cell models into its life sciences portfolio. The deal is expected to close in Q4 2026 and comes as the global cell analysis market shows significant growth.
IceCure Secures China NMPA Approval for ProSense Cryoablation System
IceCure Medical (ICCM) has received NMPA approval in China for its ProSense cryoablation system, significantly expanding its global market access. This regulatory win strengthens its international commercialization strategy and opens a new avenue for potential long-term revenue growth. While shares initially dropped, the approval is expected to enhance the company's long-term prospects in the growing cryoablation market for cancer.
West Pharmaceutical Services senior VP favorite sells $2.77m in stock
Annette F. Favorite, Senior Vice President & Chief HR Officer at West Pharmaceutical Services Inc. (NASDAQ:WST), sold approximately $2.77 million worth of company stock on September 8, 2026, after exercising stock options. Following these transactions, she beneficially owns over 16,844 shares. This sale occurred as WST shares have risen 45% in the last six months, and the company recently reported strong Q2 2026 results, beating analyst expectations and raising its full-year outlook.
West Pharmaceutical Services at Wells Fargo conference: growth outlook lifts
West Pharmaceutical Services (WST) presented a stronger growth outlook at the Wells Fargo 21st Annual Healthcare Conference, driven by a strong second quarter and increased full-year guidance for organic revenue and margin expansion. The company highlighted robust demand in high-value product components, biologics, GLP-1 programs, and regulatory-driven products like Annex 1 compliance. Despite near-term pressures from a cyberattack and a business transition in West Vantage, WST anticipates continued growth and an improving margin profile, supported by strategic investments and share repurchases.
Bank of New York Mellon Corp Acquires New Position in X-Energy, Inc. $XE
Bank of New York Mellon Corp recently acquired a new position in X-Energy, Inc. (NASDAQ:XE), purchasing 68,126 shares valued at approximately $1.25 million. This acquisition comes as X-Energy faces challenges, including a 9.9% drop in share price and a larger-than-expected quarterly loss of $0.15 per share, despite a significant 154% increase in revenue. Analyst sentiment for X-Energy is mixed, with an overall "Hold" consensus and an average price target of $34.25.
The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?
The Cooper Companies (COO) is set to announce its fiscal third-quarter 2026 earnings on September 9, with analysts expecting $1.1 billion in sales and $1.11 EPS. The company's CooperVision business, improving fertility trends in CooperSurgical, and operational efficiencies are expected to drive performance, despite anticipated headwinds in the Asia Pacific region. However, the Zacks Model does not conclusively predict an earnings beat, as COO currently holds a Zacks Rank #4 (Sell).
